Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the agreement were not disclosed.
Nona Biosciences’ Harbour Mice platform is recognized for its potential to generate a broad spectrum of conventional and novel heavy chain only (HCAb) antibodies that are fully human. These antibodies are characterized by high affinity, excellent solubility, and developability, which are crucial for enhancing the efficacy and precision of advanced therapies. The platform’s technology has undergone clinical validation, enjoys global patent protection, and has garnered worldwide recognition and endorsement within the biopharmaceutical industry.- Flcube.com
